Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials
Authors:
Open Access
- 29 February 2024
- journal article
- review article
- Published by Microbiology Society in Journal of General Virology
- Vol. 105 (2) , 001965
Abstract
Background. Chikungunya virus (CHIKV) causes chikungunya fever and has been responsible for major global epidemics of arthritic disease over the past two decades. Multiple CHIKV vaccine candidates are currently undergoing or have undergone human clinical trials, with one vaccine candidate receiving FDA approval. This scoping review was performed to evaluate the ‘efficacy’, ‘safety’ and ‘duration of protection’ provided by CHIKV vaccine candidates in human clinical trials. Methods. This scoping literature review addresses studies involving CHIKV vaccine clinical trials using available literature on the PubMed, Medline Embase, Cochrane Library and Clinicaltrial.gov databases published up to 25 August 2023. Covidence software was used to structure information and review the studies included in this article. Results. A total of 1138 studies were screened and, after removal of duplicate studies, 12 relevant studies were thoroughly reviewed to gather information. This review summarizs that all seven CHIKV vaccine candidates achieved over 90 % seroprotection against CHIKV after one or two doses. All vaccines were able to provide neutralizing antibody protection for at least 28 days. Conclusions. A variety of vaccine technologies have been used to develop CHIKV vaccine candidates. With one vaccine candidate having recently received FDA approval, it is likely that further CHIKV vaccines will be available commercially in the near future.Keywords
Funding Information
- National Health and Medical Research Council (1154347)
- National Health and Medical Research Council (1122897)
This publication has 72 references indexed in Scilit:
- An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelopeThe Microbe, 2023
- Reporting scoping reviews—PRISMA ScR extensionJournal of Clinical Epidemiology, 2020
- Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability OutcomesJAMA, 2020
- Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trialInternational Journal of Infectious Diseases, 2019
- Antibody response and avidity of respiratory syncytial virus‐specific total IgG, IgG1, and IgG3 in young childrenJournal of Medical Virology, 2011
- Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virusVaccine, 2009
- Chimeric alphavirus vaccine candidates for chikungunyaVaccine, 2008
- Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virusVaccine, 2008
- Development of an attenuated strain of chikungunya virus for use in vaccine productionVaccine, 1986
- An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952–1953Transactions of the Royal Society of Tropical Medicine and Hygiene, 1955